2B78:F:F-iShares Healthcare Innovation UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 6.856

Change

-0.07 (-1.05)%

Market Cap

N/A

Volume

140.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.14 (-0.28%)

USD 115.48B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.70 (-1.30%)

USD 95.20B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 88.54B
FRCJ:F UBS MSCI Japan Socially Respon..

-0.04 (-0.16%)

USD 75.49B
EUNL:F iShares Core MSCI World UCITS ..

+0.11 (+0.11%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

-6.15 (-2.66%)

USD 56.16B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.04 (-0.26%)

USD 56.02B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.03 (+0.03%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

-0.11 (-0.12%)

USD 51.63B

ETFs Containing 2B78:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.97% 33% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.97% 31% F 44% F
Trailing 12 Months  
Capital Gain -22.57% 8% B- 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.57% 7% C- 26% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.90% 12% F 29% F
Dividend Return -5.90% 11% F 26% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.79% 59% D- 83% B
Risk Adjusted Return -54.62% 19% F 22% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.